When a shot eats your business model

Today, I'm digging into WW International (WW), the company best know as Weight Watchers.

They offer weight management services. For 60 years, that meant a points system, weekly meetings, a coach, and a community of people trying to lose weight together. Sold via a monthly subscription. Today it is almost entirely a digital app subscription, and increasingly it is bundled with telehealth access to GLP-1 drugs like Wegovy and Zepbound.

The big story is that WW is a company that just got disrupted by GLP-1’s, declared bankruptcy, wiped out more than a billion dollars of debt, and is now trying to reinvent itself around the very drugs derailed their previous capital structure.

A few things that stood out to me:

• The brand that defined dieting got disrupted by a drug. GLP-1 medications deliver the kind of weight loss that’s “easier” than a points system, and it happend fast. WW's core program went from category-definer to category-loser in about two years.

• Revenue fell from about $1.04 billion in 2022 to $711 million in 2025.

• They ran a 42-day prepackaged Chapter 11 in mid-2025 and erased roughly $1.15 billion of debt, more than 70% of what they owed. Net debt fell from $1.43 billion to $308 million in a single year.

• In the “prepack” bankruptcy, creditors took 91% of the new equity and old shareholders were left with 9%, via a 1-new-share-for-93-old-shares conversion.

• The FY2025 net income line says $1.05 billion, which looks incredible until you realize almost all of it is a one-time accounting gain from that debt being forgiven. Real operating income was about $46 million.

It sounds weird but bankruptcy was the easy part. Cleaning up a balance sheet is mechanical work that lawyers and lenders have done many times. But rebuilding your business model is a more daunting challenge, obviously.

Personally, I’m not concerned about drugs disrupting my Fullstack Ag business (AI course/community platform for agriculture). But AI is a risk for any internet/information business so I’m actively trying to diversify our revenue amongst one-time courses, a recurring community, in-person events, sponsorships, and we’ll be dipping our toes into selling a mix of one-time and recurring software tools.

You can’t predict the next disruption, but you can control how diversified your revenue is today.

It will be fun to see how Weight Watchers adapts to this new weight loss world we are living in.

With that, I'll see you on Thursday when I will peel back the onion on competitor Hims & Hers!

Nick

TL;DR

• WW (Weight Watchers) is the 60-year-old weight-management brand, now an almost entirely subscription digital business after shedding most of its studios and product lines.

• It makes money on recurring memberships, roughly 99% of revenue, increasingly paired with telehealth access to GLP-1 medications through its 2023 acquisition of Sequence. This medication revenue flows around WW and directly to pharmacies.

• GLP-1 drugs gutted the core program. Revenue fell from about $1.04 billion in 2022 to $711 million in 2025, and the company ran a 42-day Chapter 11 in mid-2025 to eliminate roughly $1.15 billion of debt.

• The FY2025 $1.05 billion net income is a one-time debt-cancellation gain, not operations. Real operating income was about $46 million on a 72% gross margin, and net debt dropped from $1.43 billion to $308 million.

• On the stock: since emerging from bankruptcy on June 24, 2025, WW shares are down about 35%, and the whole weight-loss complex has struggled (Hims & Hers down about 52% over the past year, Medifast down about 8%), a reminder the GLP-1 gold rush punishes even the disruptors.

• Operator takeaway: a fixed balance sheet does not fix a business model. WW still has to prove customers will pay for support on top of a drug that already works.

The 30,000-Foot View

WeightWatchers sells behavior change through a subscription. The core idea was always straightforward: losing weight is harder alone, so give people a system to follow, someone to hold them accountable, and a group of people going through the same thing. Members paid every month for points, coaching, weigh-ins, and community. The business worked because habits take time to build, and people trying to change their routines tend to stay engaged.

That model held up for decades. Then GLP-1s changed the definition of results. When a weekly shot can produce 15% to 20% body-weight loss, a points-based program starts to look slow. WW’s response has been to stop competing with the drugs and build around them. After buying the telehealth platform Sequence in 2023 for more than $100 million, WW can now connect members with clinicians who prescribe GLP-1s, then add nutrition and behavioral coaching on top. The message is simple: others can get you the prescription, but WW helps you stay healthy and keep the weight off.

The revenue mix shows how much the company has changed. The old product business, snack bars, cookbooks, and studio merchandise, has mostly disappeared. Today, WeightWatchers is essentially a subscription business.

Revenue mix (FY2024):

• Subscriptions: ~99%

• Product and other: ~1%

By geography, the United States is about 69% of revenue, Germany about 11%, and the rest of the world the remaining 20%.

Key Stats

• Market cap: ~$185M

• FY2025 revenue: ~$711M

• FY2025 gross margin: ~72%

• Net debt: ~$308M (down from ~$1.43B a year earlier)

• Employees: ~3,500

• 1Y total return: not meaningful (down ~35% since the June 24, 2025 emergence)

• Industry: Personal Products and Services (Consumer Cyclical)

Company History

• 1963: Jean Nidetch hosts the first Weight Watchers meeting in Queens, New York, turning her own weight-loss group into a business.

• 1978: H.J. Heinz acquires Weight Watchers, scaling the brand through food products.

• 1999: European investment firm Artal Group buys Weight Watchers from Heinz.

• 2001: IPO on the New York Stock Exchange.

• 2015: Oprah Winfrey buys roughly a 10% stake and joins the board. The stock soars on the news.

• 2019: Rebrands from Weight Watchers to "WW" in an attempt to broaden from dieting into wellness.

• 2023: Acquires Sequence, a GLP-1 telehealth platform, for more than $100 million, entering the weight-loss medication market.

• 2024: Oprah departs the board and donates her stock as GLP-1 drugs take hold. Shares drop about 25% on the announcement. CEO Sima Sistani exits later in the year.

• 2025 (Feb): Tara Comonte named CEO to lead the turnaround.

• 2025 (May to June): Files a prepackaged Chapter 11 on May 6, emerges June 24 with roughly $1.15 billion of debt eliminated and creditors holding 91% of the new equity.

• 2025 (Dec): Relaunches under the old "Weight Watchers" name with a new app, a GLP-1 focused program, and added AI features.

Show Me the Money

Standout financial features:

• Net debt collapsed from $1.43 billion to $308 million in one year. That is the single biggest number in this report, and it came from the bankruptcy, not from operations.

• Gross margin actually expanded the whole way down, from about 60% to 72%, as the low-margin product business fell away and the mix shifted to pure digital subscriptions.

• That $1.05 billion FY2025 net income is a mirage. It is a one-time gain from debt being cancelled in reorganization. Strip it out and the company earned about $46 million of operating income on $711 million of revenue.

Financial Data

(FY2022's deep operating loss was driven by a large goodwill impairment as the GLP-1 threat became clear. FY2025 is the first post-bankruptcy fiscal year.)

Stock Performance

A quick warning on the returns. WW went through a 1-for-93 share conversion in the reorganization, and existing shareholders were left with just 9% of the new company. That means any return measured across the bankruptcy is not comparable, so the long-run cells below are marked not meaningful on purpose.

Since emerging from Chapter 11 on June 24, 2025, the new shares are down about 35%.

1-year peer comparison:

I picked these two on purpose. Hims & Hers (HIMS) is the GLP-1 telehealth disruptor that WW now competes with directly, and Medifast (MED) is the other legacy diet company (OPTAVIA) getting hollowed out by the same drugs. Here is the operator-level read: the entire weight-loss complex had a brutal year. Even Hims, the supposed winner, is down about 52% after its GLP-1 boom cooled and a Novo Nordisk partnership unwound. When the disruptor's stock and the incumbents' stocks all fall together, that is a sign the economics of this whole category are still being figured out in real time.

The N.O.O.B. Nine — Competitive Powers

The Nerd Out on Business Nine is made up of Hamliton Helmer's famous "7 Powers" of competitive advantage (Scale Economies, Network Economies, Counter-Positioning, Switching Costs, Branding, Cornered Resource, and Process Power) combined with two of my own (Data Flywheel and Distribution Advantage).

Average Score: 2.4/5 - A powerful but fading brand sitting on top of a business model that the GLP-1 era turned upside down. The moat is mostly the name, and the name alone is not enough.

Memorable Marketing

WeightWatchers marketing has always run on one thing: belief. Real people, real before-and-after stories, and for a long stretch, one very famous believer.

Notable campaigns and tactics:

• The Oprah era (2015 to 2024): Oprah Winfrey bought a stake, joined the board, and became the face of the brand. The "Oprah effect" sent the stock soaring on the day she joined. It was celebrity endorsement fused with equity ownership, the strongest possible alignment, right up until she left.

• The Points system (decades): SmartPoints, then PersonalPoints, turned the messy act of eating into a simple, gamified, ownable framework. It was the original gamification of dieting and the thing members actually talked about.

• Rebrand to "WW" (2019): An attempt to shed the word "diet" and reposition as broad "wellness." It never fully landed.

• Back to "Weight Watchers" plus GLP-1 (2025): After the bankruptcy, the company reclaimed its heritage name and repositioned as the place to do GLP-1 drugs "the right way," with coaching and support around the medication.

Tactical takeaways:

1. Celebrity equity stakes align incentives beautifully, but they concentrate your brand risk in one person. When Oprah left, a lot of perceived value left with her.

2. A proprietary framework like Points turns a generic behavior into something you own and customers can name.

3. When your category shifts, a famous brand can flip from asset to liability if it is synonymous with the old way of doing things.

4. Reclaiming a heritage name can signal focus, but it only works if the product behind it actually changed.

AI Uses & Opportunities

Current exposure:

• The relaunched app (December 2025) adds AI features for tracking and coaching.

• The Sequence telehealth layer matches members to clinicians and manages prescriptions and follow-up digitally.

Future opportunities:

• AI coaching as the differentiator. The whole bet is that a GLP-1 script is a commodity but the support around it is not. AI can deliver that support at subscription-friendly margins.

• Churn prediction and retention. GLP-1 users famously drop off, so predicting and intercepting that churn is worth real money.

• Photo-based food logging and AI nutrition guidance to lower the friction that makes people quit tracking.

• Medication adherence and side-effect nudges that make WW genuinely useful to someone on a drug.

• Outcomes data as a marketing weapon: proving "WW plus a GLP-1 keeps weight off better than the drug alone" would be a defensible claim few rivals could match.

Bumps in the Road

• The core behavioral program is in structural decline. The drugs simply work better and faster, and no amount of coaching changes that math.

• GLP-1 telehealth is brutally competitive and getting commoditized. Hims, LifeMD, Ro, Noom, and the drug makers' own direct channels are all chasing the same customer, and even the leaders' stocks are volatile.

• Revenue has fallen every year since 2022, from about $1.04 billion to $711 million. The slide has not stopped yet.

• The company still carries $465 million of new debt due 2030. It is less indebted, not debt-free.

• WW depends on supply and access to medications it does not control. If a drug maker changes terms or sells direct, WW's value-add gets squeezed.

Your Swipe File

• A balance sheet can be fixed in 42 days. A broken business model cannot. Bankruptcy reset WW's debt but not its demand.

• When a pill does your product's job better, sell the thing the pill cannot: support, accountability, and durable results.

• Read the net income line with suspicion. WW's billion-dollar 2025 "profit" was debt forgiveness, not earnings.

• Owning a category's name is an asset until the category gets disrupted.

• Buying your way into a disruptive trend (Sequence) can be faster than building it.